Advantages and drawbacks of AAV vector-mediated gene transferAAV protocol Download
a) Advantages of AAV-mediated gene transfer
AAV has been developed into a very attractive candidate for creating viral vectors for gene therapy and the creation of isogenic human disease models due to various advantages. 1) Superior biosafety rating. The wild type AAV has not currently been known to cause disease in vivo, and further security of recombinant AAV gene delivery in vivo is ensured after removal of most AAV genome elements. 2) Low immunogenicity. AAV causes a very mild immune response in vivo, lending further support to its apparent lack of pathogenicity during gene delivery. 3) Broad range of infectivity. AAV can infect both dividing and quiescent cells in vivo, allowing gene delivery to a highly diverse range of cell types. 4) Stable expression. Long term gene delivery in vivo can be mediated by AAV.
b) Drawbacks of AAV-mediated gene transfer
Although adenovirus benefits a great deal of disease therapies, it does present some drawbacks.
1) The major drawback is its limited cloning capacity (less than 4.7kb) of the vector, which restricts its use in gene delivery of large genes.(Table 3) . 2) Generation of neutralizing antibodies against AAV in the Non-Human Primates (NHP) and human, may attenuate the cure effect of AAV-mediated gene therapy .
|Genome||ss RNA||ss RNA||ds DNA||ss DNA|
|Time to peak expression||72h||72h||36h-72h||Cell: 7 days;
Animals: 2 weeks
|Sustainable time||About 3 weeks||Stable expression||Transient expression||> 6 months|
|Cell Type||Most Dividing||Most Dividing/Non-Dividing Cells||Most Dividing/Non-Dividing Cells||Most Dividing/Non-Dividing Cells|
|Titer||10^7 TU/ml||10^8 TU/ml||10^11 PFU/ml||10^12 vg/ml|
|Animal experiment||Suitable||Low efficiency||Lowest efficiency||Most suitable|
View Adeno-associated virus (AAV vector) Knowledge Base>>
Other knowledge bases
AAV Knowledge Base
CRISPR/Cas9-gRNA system Knowledge Base
Adenovirus Knowledge Base
Transfection Knowledge Base
Lentivirus Knowledge Base
Advanced cell therapy